BioSpace News Archive

Alloy Therapeutics, a biotechnology ecosystem company, announced an antibody discovery collaboration spanning multiple precision immuno-oncology programs for Normunity, a biotech company that recently announced its $65 million Series A financing.

Tenaya Therapeutics, Inc. announced the pricing of its underwritten public offering of 22,613,307 shares of its common stock at a price to the public of $2.60 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 6,236,693 shares of its common stock at a purchase price of $2.599 per each pre-funded warrant.

EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, is pleased to announce that the Company’s WiSE® technology will be featured at the 15th Asia Pacific Heart Rhythm Society Scientific Session in Singapore from the 18th to the 20th of November.

KAHR and the Myeloma Investment Fund announced that the MIF has invested in KAHR to explore the potential of DSP107, KAHR’s lead immunotherapy drug candidate, for the treatment of multiple myeloma.

SonoMotion announces it has secured USD$12.4 million in Series C funding co-led by integrated global urology leader Advanced MedTech Holdings and SolarCity co-founder Lyndon Rive.

Immunic, Inc today reported newly available data from its phase 2 EMPhASIS trial of lead asset, vidofludimus calcium (IMU-838), in relapsing-remitting multiple sclerosis (RRMS).

Day One Biopharmaceuticals today announced that management will participate in a fireside chat at the Piper Sandler 34 th Annual Healthcare Conference on Tuesday, November 29, 2022 at 11:00 a.m. EST.

Lucira Health, Inc. announced the launch of Lucira Connect, a new virtual care program that allows Lucira test users the ability to test, learn about treatment options, access a telehealth consultation, and if appropriate, receive a prescription all from home for only the $29 price of the test, excluding prescription costs.

Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) today announced nine-month durability of effect in the extension cohort of the PEARL-1 study of KB301, an investigational gene-based treatment designed to address the underlying biology of aging skin for improvement of fine lines and wrinkles.

Omega Therapeutics, Inc. today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022, at 8:00 a.m. ET.